Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mayo Clinic researchers document safer treatment for atrial fibrillation

30.09.2002


Mayo Clinic researchers report that the risk of stroke that sometimes results from a common treatment for atrial fibrillation can be minimized when the patient takes anticoagulation medication prior to the procedure.



The researchers report on the largest single medical center experience regarding safety of elective direct current (DC) cardioversion of atrial fibrillation. DC cardioversion is the electronic restoration of the heart’s normal rhythm.

Atrial fibrillation affects more than 2.5 million people in the United States. It is characterized by an irregular and rapid beating of the heart’s atrial chambers and results when the normal electrical conduction system of the atria is not functioning properly. It is estimated that atrial fibrillation is responsible for more than 70,000 strokes each year in the United States. The prevalence of atrial fibrillation increases with age.


The researchers found that the rate of stroke or other embolic happenings -- clots or blockages of the blood vessels -- occurring in a patient after cardioversion was less than 1 percent. In the study, 834 successful cardioversions were performed in 717 patients from 1990 through 1994. Researchers said that use of adequate anticoagulation medication prior to the procedure reduced the risk of thromboembolism.

Mayo Clinic researchers involved in the study were Federico Gentile, M.D.; Bijoy Khanderia, M.D.; James Seward, M.D.; Christine Lohse, BSc; Win-Kuang Shen, M.D.; Kent Bailey, Ph.D.; Samantha Montgomery, MSc; Belli Burger, BSc and A. Jamil Tajik, M.D. Abdou Elhendy, M.D., Ph.D. is now with the University of Nebraska, Omaha.

Warren Manning, M.D., and Peter Zimetbaum, M.D., of Beth Israel Deaconess Medical Center in Boston, write in an accompanying editorial that clinicians must assess the individual patient to determine the benefits of cardioversion.

"If the decision favors cardioversion, (the researchers) have provided further proof of the efficacy of three to four weeks of warfarin anticoagulation before cardioversion," the editorialists write about the current approach to treatment.

Additional contact information:
John Murphy
507-284-5005 (days)
507-284-2511 (evenings)
e-mail: newsbureau@mayo.edu

John Murphy | EurekAlert!

More articles from Health and Medicine:

nachricht Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Foods of the future
15.08.2018 | Georg-August-Universität Göttingen

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

Smallest transistor worldwide switches current with a single atom in solid electrolyte

17.08.2018 | Physics and Astronomy

Robots as Tools and Partners in Rehabilitation

17.08.2018 | Information Technology

Climate Impact Research in Hannover: Small Plants against Large Waves

17.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>